Therapeutic advances in type 1 diabetes (T1DM) are currently focused on developing a closed-loop control system using a continuous glucose monitor (CGM), subcutaneous insulin delivery, and a control algorithm. Because a CGM assesses blood glucose indirectly (and therefore often inaccurately), it limits the effectiveness of the controller. In order to improve the quality of CGM data, a series of analyses are suggested. These analyses evaluate and compensate for CGM errors, assess risks associated with glucose variability, predict glucose fluctuation, and forecast hypo- and hyperglycemia. These analyses are illustrated with data collected using the MiniMed CGMS® (Medtronic, Northridge, CA) and Freestyle Navigator(™) (Abbott Diabetes Care, Alameda, CA). It is important to remember that traditional statistics do not work with CGM data because consecutive CGM readings are highly interdependent.
Keywords: CGM; continuous glucose monitoring; hypoglycemia; prediction methods; time series.